Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for Eteplirsen on Wednesday, July 24, 2013
(firmenpresse) - CAMBRIDGE, MA -- (Marketwired) -- 07/23/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Wednesday, July 24, 2013, to provide a regulatory update for eteplirsen, its lead product candidate for the treatment of Duchenne muscular dystrophy (DMD).
The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 35357086. Please specify to the operator that you would like to join the "Sarepta Therapeutics Regulatory Update Call." The conference call will be webcast live under the events section of Sarepta's website at and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at .
Sarepta Investor Contact:
Erin Cox
857.242.3714
Sarepta Media Contact:
Jim Baker
857.242.3710
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.07.2013 - 14:59 Uhr
Sprache: Deutsch
News-ID 1248118
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
CAMBRIDGE, MA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for Eteplirsen on Wednesday, July 24, 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
Sarepta Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
